Alaunos Therapeutics Announces Board and Officer Changes
Ticker: TCRT · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: TCRT
TL;DR
Alaunos Therapeutics (TCRT) filed an 8-K detailing board/officer changes and compensation. Watch for strategic shifts.
AI Summary
Alaunos Therapeutics, Inc. announced on July 15, 2025, changes related to its board of directors and officers, including the departure of certain individuals and the election of new directors. The company also reported on compensatory arrangements for its officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and officer changes can indicate internal instability or strategic pivots, which carry inherent risks for a company.
Key Numbers
- 001-33038 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-1475642 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- July 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Houston, TX (location) — Principal executive offices
FAQ
What specific changes were made to the board of directors and officers of Alaunos Therapeutics?
The filing indicates the departure of certain directors or officers and the election of new directors, as well as details on compensatory arrangements for certain officers.
What is the significance of filing a Form 8-K?
A Form 8-K is a report of "unscheduled material events or corporate changes" that could be of importance to investors.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on July 15, 2025.
What is Alaunos Therapeutics' principal executive office address?
The principal executive offices are located at 2617 Bissonnet St Suite 233, Houston, TX 77005.
What is the company's former name?
The company was formerly known as ZIOPHARM ONCOLOGY INC and EASYWEB INC.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).